`
`__________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`__________
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVARTIS PHARMA AG,
`NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owners
`
`__________
`
`IPR2021-00816
`U.S. Patent 9,220,631
`
`__________
`
`NOTICE OF CERTIFICATION OF WORD COUNTS FOR
`PATENT OWNERS’ SURREPLY TO PETITIONER’S REPLY
`
`
`
`
`
`Patent Owner Novartis hereby supplements the Certificate of Word Count
`
`for the Patent Owner’s Surreply to Petitioner’s Reply, filed on May 26, 2022. The
`
`Certificate of Word Count was inadvertently not included in Patent Owner’s
`
`Surreply to Petitioner’s Reply, filed on May 26, 2022.
`
`CERTIFICATE OF WORD COUNT
`
`Under 37 C.F.R. § 42.24(b)(1), the undersigned certifies that the foregoing
`
`Patent Owner’s Surreply to Petitioner’s Reply contains 5,565 words, excluding table
`
`of contents, and a certificate of service or word count, as measured by the word-
`
`processing system used to prepare this paper. 37 CFR. § 42.24(a)(1).
`
`
`Dated: May 27, 2022
`
`By:
`
`
`/Elizabeth J. Holland/
`Elizabeth J. Holland (Reg. No. 47,657)
`Lead Counsel for Patent Owners
` ALLEN & OVERY LLP
`1221 Avenue of the Americas
`New York, NY 10020
`Phone: (212) 610-6300
` elizabeth.holland@allenovery.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`A copy of this Notice of Certificate of Word Count for Patent
`
`Owners’ Surreply to Petitioner’s Reply has been served on Petitioner’s
`
`attorneys of record as follows via electronic mail:
`
`Elizabeth Stotland Weiswasser
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8022
`F: 212-310-8007
`elizabeth.weiswasser@weil.com
`USPTO Reg. No. 55,721
`Anish R. Desai
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`F: 212-310-8007
`anish.desai@weil.com
`USPTO Reg. No. 73,760
`
`Natalie Kennedy
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`F: 212-310-8007
`natalie.kennedy@weil.com
`USPTO Reg. No. 68,511
`Andrew Gesior
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`
`
`
`
`
`
`
`
`
`
`
`
`
`T: 212-310-8730
`F: 212-310-8007
`andrew.gesior@weil.com
`USPTO Reg. No. 76,588
`
`Brian E. Ferguson
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite
`600
`Washington, D.C. 20036
`T: 202-682-7000
`F: 202-857-0940
`brian.ferguson@weil.com
`USPTO Reg. No. 36,801
`
`Christopher M. Pepe
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite
`600
`Washington, D.C. 20036
`T: 202-682-7000
`F: 202-857-0940
`christopher.pepe@weil.com
`USPTO Reg. No. 73,851
`
`Regeneron.IPR.Service@weil.com
`
`Attorneys for Regeneron Pharmaceuticals, Inc.
`Dated: May 27, 2022
`By:
`/Frank ReDavid/
`
`
`
` Frank ReDavid
`
`
`
` Litigation Specialist
`
`
`
` Allen & Overy LLP
`
`
`
`
`
`
`
`
`
`
`
`
`
`